LEO Pharma

LEO Pharma A/S acquires rights to develop and market brodalumab for moderate-to-severe psoriasis outside of Europe

Share

New sub-licensing agreement allows LEO Pharma to help more people around the world with an additional treatment option for psoriasis. 

August 13th, 2019, Ballerup, Denmark: LEO Pharma A/S, a global leader in medical dermatology, today announced it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum® in the European Union) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licencing agreement with Bausch Health Ireland Limited. The new agreement includes countries with significantly high unmet need, such as Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia.

This complements the ongoing licensing agreement between LEO Pharma A/S and AstraZeneca to develop and market brodalumab for the treatment of moderate-to-severe psoriasis in Europe. To date, LEO Pharma A/S has successfully launched brodalumab in 18 countries. Outside of the EU, Bausch Health Companies Inc. through a licensing agreement with AstraZeneca, has owned the global commercial rights for brodalumab except in Japan and other Asian countries, where the rights are owned by Kyowa Kirin Co., Ltd.

Under the new arrangement terms, Bausch Health has granted LEO Pharma A/S an exclusive license to its global rights to brodalumab but continues to hold the rights for the US and Canada.  

“This new agreement underlines our commitment to expand our successful dermatology portfolio into innovative therapies and new indications,” said Catherine Mazzacco, President and CEO of LEO Pharma. “The burden of living with psoriasis is often underestimated, and we want to help patients at all stages of their condition. With the brodalumab agreement, we are bringing a new option to many more people across the globe living with psoriasis.”

Brodalumab received marketing authorization by the European Commission in July 2017 and is currently indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.[1]

For more information about LEO Pharma, visit www.leo-pharma.com.

Facebook: www.facebook.com/LEOPharmaAS

LinkedIn: www.linkedin.com/company/leo-pharma

Twitter: www.twitter.com/leohealthyskin

YouTube: www.youtube.com/leopharmaglobal

#ENDS#

 

NOTE TO EDITORS

About psoriasis

An estimated 125 million people worldwide live with psoriasis.[2] It is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin.[3] The most frequently reported symptoms include thickening and scaling of the skin, itching and erythema (superficial reddening of the skin, usually in patches).[3]

Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person’s life.[3] People with psoriasis, especially those with more severe symptoms, are also at increased risk of developing other serious associated conditions,[4] including heart disease[5],[6],[7] and metabolic diseases (a combination of diabetes, high blood pressure and obesity).[8] Mental health complications, such as depression and anxiety, are also more common in people with psoriasis.[9] According to the World Health Organization, the burden of living with psoriasis is underestimated and it urges for action to fight stigma and improve treatment.[3]

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.

 

Contact:

Henrik Kyndlev
+45 3140 6180
hdtdk@leo-pharma.com

  

References

[1]      European Commission, Community register of medicinal products for human use, Kyntheum® (brodalumab). Available at: http://ec.europa.eu/health/documents/community-register/html/h1155.htm(Accessed March 2019).

[2]     The International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com/(Accessed March 2019).

[3]       World Health Organization (WHO). Global Report on Psoriasis. Available at: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf(Accessed March 2019).

[4]     Reich K. Eur Acad Dermatol Venereol 2012;26(2):3–11.

[5]     Gelfand JM, et al. JAMA 2006;296:1735–41.

[6]     Ahlehoff O, et al. Eur Heart J 2012;33:2054–64.

[7]     Lowes MA, et al. Ann Rev Immunol 2014;32:227–35.

[8]     Langan SM, et al. J Invest Dermatol 2012;132(3 Pt 1):556–562.

[9]     Dalgard F, et al. JID 2015;135(4):984 –991.

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma completes the acquisition of Bayer’s pre-scription dermatology business2.7.2019 09:00:00 CESTPress release

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies first announced the proposed transaction on July 31, 2018 and completed the first step of the acquisition with the closing in the United States on September 4, 2018. Today’s second and final closing covers all other countries.

LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management10.5.2019 10:27:35 CESTPress release

Ballerup, Denmark, May 10, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced the appointment of Beth-Anne Lang, Vice President and Head of Global Regulatory Affairs and Christine Garrett, Vice President and Head of Global Project Manage-ment. Both will join LEO Pharma on May 13.

New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis25.4.2019 09:12:24 CESTPress release

Ballerup, Denmark, April 25, 2019: LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom